Extended Data Fig. 6: Percent change from baseline in total lesion activity by 18F-NaF PET and total volume of HO lesions by CT over time for pre-existing lesions (AHO). | Nature Medicine

Extended Data Fig. 6: Percent change from baseline in total lesion activity by 18F-NaF PET and total volume of HO lesions by CT over time for pre-existing lesions (AHO).

From: Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

Extended Data Fig. 6: Percent change from baseline in total lesion activity by 18F-NaF PET and total volume of HO lesions by CT over time for pre-existing lesions (AHO).

a, LS mean percent change from baseline in TLA by 18F-NaF PET over 28 weeks. b, LS mean percent change from baseline of total HO lesion volume assessed by CT. LS means and SEs were estimated using a MMRM. This model included fixed categorical effects of treatment group, gender, time point, treatment-by-time point interaction, as well as the continuous fixed covariates of baseline value. 18F-NaF PET, fluorine-18-labeled sodium fluoride positron emission tomography; AHO, active heterotopic ossification analysis set; BL, baseline; CT, computed tomography; HO, heterotopic ossification; LS, least squares; MMRM, mixed-effect model for repeated measures; Q4W, every 4 weeks; SE, standard error.

Back to article page